To assess the clinical usefulness of published guidelines for the use of orlistat, by studying whether weight loss ! 2.5 kg during a 4 week dietary lead-in period, and weight losses of ! 5% after 12 weeks and ! 10% after 6 months of drug therapy predict weight loss and risk factor changes after 2 years. DESIGN: A retrospective analysis of pooled data from 2 multicentre, randomised, placebo-controlled clinical trials with similar design. SETTING: Twenty-nine centres throughout Europe. PARTICIPANTS: Two hundred and twenty men and women (BMI 28 -43 kg=m 2 ) who completed 2 years of treatment. INTERVENTION: After a 4 week hypocaloric diet plus placebo, 2 years of treatment with orlistat 120 mg tid, plus a hypocaloric diet for the first year and a weight maintenance diet in year two. MAIN OUTCOME MEASURES: Weight loss and obesity-related risk factor changes. RESULTS: Weight loss ! 5% body weight after 12 weeks of diet plus orlistat therapy was a good indicator of 2 year weight loss, whereas weight loss of ! 2.5 kg during the 4 week lead-in and ! 10% after 6 months did not add significantly to the prediction of 2 year outcomes. Patients who lost ! 5% of their weight at 12 weeks (n ¼ 104, 47.3%) lost significantly more weight after 2 years than others: 711.9% (95% confidence interval (CI) 713.4% to 710.3%) vs 74.7% (75.7% to 73.7%) (P ¼ 0.0001), and had significantly greater reductions in total cholesterol, LDL-cholesterol, triglycerides, glucose, insulin, and blood pressure. Among those who achieved ! 5% weight loss at 12 weeks, the overall health benefits were not significantly greater in patients who went on to lose ! 10% body weight at 6 months compared with those who did not achieve ! 10% weight loss by month 6. CONCLUSIONS: Of the criteria currently suggested for assessing response to orlistat treatment, weight loss of ! 5% at 12 weeks accurately predicts sustained improvements in weight and major risk factors at 2 years, while other suggested criteria are less useful.
Introduction
Weight loss of 5 -10% improves most obesity-related cardiovascular and metabolic abnormalities, 1 -3 but the limited long-term success of conventional approaches in maintaining these benefits 4, 5 has increased the interest in pharmacotherapy as an adjunct to obesity management. 6 -8 Identification of patients most likely to respond to and benefit from adjunctive pharmacotherapy is important, as it is likely to enhance long-term outcomes and minimise the risks of treatment. Clinical trials indicate that patients who respond to drug treatment with early weight loss generally tend to continue to respond positively, while those who are initially unresponsive are likely to remain so. 9 -11 Some treatment algorithms recommend discontinuing drug therapy in patients who do not achieve early weight loss, eg < 2 kg after 4 weeks 12 or < 5% of initial weight after 12 weeks of drug treatment. 13, 14 At present there is little consistent published evidence to support these specific recommendations and to inform evidence-based guidelines for the use of pharmacotherapy in obesity.
The gastrointestinal lipase inhibitor orlistat in combination with a hypocaloric diet has been shown to be an effective weight management agent in 2 year randomised, placebocontrolled trials. 15 -17 The prescribing information for orlistat in Europe 18 recommends that only patients who have previously lost at least 2.5 kg by diet alone in a 4 week period, as an indication of their capacity to comply with the prescribed dietary changes, should commence drug treatment and only those who lose a further 5% or more of body weight after 12 weeks should continue taking the drug. The patients who are prescribed orlistat 'as per licence' are thus expected to achieve enhanced weight loss as well as improvements in obesity-related health conditions. However, the group mean data, usually required for regulatory purposes, do not provide a clear indication of the effectiveness of the drug in routine clinical practice, because the active arm includes patients with a range of responses to treatment. 19 The recent guidance on the use of orlistat for the treatment of obesity issued by the National Institute for Clinical Excellence 14 proposes an additional criterion that only patients who achieve weight loss ! 10% after 6 months should continue drug therapy. We pooled data from two large 2 year studies in order to: 1) study the validity of these recommendations and their ability to identify patients who benefit most from orlistat treatment; and 2) quantify the clinical benefit of orlistat treatment in patients who satisfy them.
Methods
We present here a retrospective analysis of data pooled from two large 2 year European, multicentre, randomised and placebo-controlled trials of similar design. 15, 17 In both studies, overweight and obese men and women (BMI 28 -43 kg=m 2 ) aged ! 18 y were enrolled into a 4 week, singleblind, lead-in period during which they received placebo and a hypocaloric diet, containing 30% of energy as fat, designed to induce a 2090 kJ daily energy deficit. Patients who completed this lead-in period were randomised to 2 years of double-blind treatment with orlistat 120 mg tid or placebo. In the first year the hypocaloric diet was continued and in the second year, energy prescription was increased to provide a weight-maintenance diet.
In order to evaluate whether early response to orlistat therapy predicts long-term weight maintenance and health benefits, only data from subjects who completed 2 years of treatment with diet plus orlistat were analysed.
Body weight was measured during the lead-in period (weeks 74 and 72), at randomisation (week 0), and at regular intervals during the 2 year treatment period.
Secondary efficacy parameters included serum lipid concentrations (total cholesterol, LDL-cholesterol, HDLcholesterol, triglycerides), blood pressure and fasting serum glucose and insulin concentrations, measured at various intervals during the study as described previously. 15 Both trials were conducted in accordance with the Declaration of Helsinki. Ethics committees at all participating centres approved the study protocols and all patients gave informed consent.
Statistical analysis
The aim of this analysis was to assess the 2 year treatment outcomes of pharmacological weight management between subgroups according to weight loss criteria recommended for the initiation and continuation of pharmacotherapy, 14 rather than to assess mean differences between orlistat and placebo, which have been published previously. We therefore categorised the subjects who completed the 2 year study according to weight loss ( < 2.5 kg or ! 2.5 kg) during the 4 week placebo lead-in period (week 74 to week 0). Within each of these two categorical groups, patients were further categorised according to whether they lost more or less than 5% weight from randomisation (week 0; baseline) to week 12 of orlistat treatment. Thus, this analysis uses a 2Â2 factorial design in which 4 week response (weight loss of < 2.5 or ! 2.5 kg during the 4 week lead-in) and 12 week response are grouping factors. Two-way analysis of variance was applied to test for the statistical significance of the main effects of the grouping factors. 20 The predictive value of 6 month weight loss ! 10% from randomisation (baseline) was analysed using a single-factor model, owing to the overlap and hence redundancy between the 0 -3 month and 0 -6 month periods. Similar analyses were applied to test the significance of changes in risk factors at the end of 1 and 2 years. Changes in body weight and all risk factor variables except blood pressure were expressed as percentage change from initial value to 1 year and 2 year values. For all analyses, the P < 0.05 level was considered statistically significant.
Results

Patient disposition
A total of 220 patients completed 2 years of orlistat treatment and had complete data at all the times of interest. The distribution of the subjects according to whether they met the 3 criteria for response to treatment is shown in Figure 1 . Also shown in Figure 1 is the weight loss achieved by these subjects after 1 and 2 years. The demographic characteristics of these subjects are shown in Table 1 . During the 4 week dietary lead-in period, 118 patients (53.66%) achieved ! 2.5 kg weight loss whilst 102 patients (46.4%) lost < 2.5 kg. During the first 12 weeks of treatment with diet Early response predicts 2 year weight loss A Rissanen et al plus orlistat, 104 patients (47.3%) achieved weight loss of !5% of body weight from baseline, whereas 116 patients (52.7%) did not; after 6 months, 47=220 patients (21.4%) lost at least 10% of body weight from baseline, while 173 patients (78.6%) did not. There were no significant differences in the demographic characteristics among any of these subgroups.
Weight loss and maintenance at 2 years
The subjects who lost ! 2.5 kg during the lead-in, irrespective of their weight loss at week 12, achieved an average weight loss of 79.4% (95% confidence interval (CI) 710.8% to 77.9%) at 2 years. In comparison, an average weight loss of 76.6% (95% CI 77.9% to 75.2%) was achieved by subjects who lost < 2.5 kg during the lead-in. 
This was not statistically significant, although the 4 week lead-in did have predictive value at 1 year ( Table 2 ).
The subjects who lost ! 5% of body weight during the first 12 weeks of drug therapy achieved significantly greater weight loss after 2 years than those who lost < 5%: 711.9 AE 0.8% (95% CI 713.4% to 710.3%) vs 74.7 AE 0.5% (95% CI 75.7% to 73.7%); P ¼ 0.0001. Of the 116 patients who did not achieve ! 5% weight loss from baseline at 12 weeks, 29 patients went on to lose ! 5% and 8 patients lost ! 10% from their initial weight after 2 years.
The 47 subjects (21.4%) who achieved ! 10% weight loss after 6 months of drug treatment, all of whom had also lost at least 5% at 3 months, had a weight loss of 15% (95% CI 717.6% to 712.3%). Among the subjects who lost ! 5% after 12 weeks, those who also achieved ! 10% weight loss at 6 months had greater 2 year weight loss than those who did not (Figure 1) .
Irrespective of classification, a total of 179 (81.4%) and 140 patients (63.6%) experienced ! 5% weight loss from their initial weight at year 1 and year 2, respectively. The corresponding number of patients with ! 10% weight loss at year 1 and 2 were 115 (52.3%) and 77 (35.0%), respectively.
Risk factors at 2 years
Changes in risk factors after 1 and 2 years are shown in Figure 2 . After 2 years, patients who lost ! 5% of body weight within the first 12 weeks of treatment had significantly greater improvements than patients who lost < 5% after 12 weeks in total cholesterol (710.7 AE 1.3 vs 74.9 AE 1.3%; P ¼ 0.002), LDL-cholesterol (711.3 AE 1.8 vs 74.8 AE 1.9%; P ¼ 0.015), triglycerides (716.2 AE 3.2 vs þ3.3 AE 4.2%; P < 0.001), fasting glucose (75.3 AE 0.8 vs 70.3 AE 1.7%; P ¼ 0.012), fasting insulin (721.9 AE 4.2 vs 78.8 AE 4.2%; P ¼ 0.034), and systolic (79.5 AE 1.3 vs 73.7 AE 1.5 mmHg; P ¼ 0.005) and diastolic blood pressure (75.4 AE 0.9 vs 72.2 AE 0.9 mmHg; P ¼ 0.017). Weight loss in the 4 week lead-in had no influence on cardiovascular risk factor changes after 2 years of treatment. Although 2 year weight loss was greater in the subjects who achieved both the 12 week and 6 month benchmarks compared with those who failed to achieve an additional 5% weight loss between 12 weeks and 6 months, none of the 2 year risk factor changes differed significantly according to 6 month weight loss (Figure 3 ).
Discussion
The worldwide increase in the burden of obesity has led to recognition of an urgent need to improve strategies for prevention and options for long-term management, including evidence-based pharmacotherapy. The aims of the present analysis were to evaluate whether the European (EMEA) prescription indication and the recent NICE guidance for the use of orlistat as a weight loss agent indeed identify the most appropriate candidates for drug treatment and to quantify the expected long term benefits if the guidelines are followed. The results show that weight loss of ! 5% after 12 weeks of drug therapy is indeed a useful predictor of weight loss sustained for 2 years, consistent with the NICE guidance and European prescribing criteria. Moreover, 100% of the patients who met the 6 month weight loss criterion from the NICE guidance would have been correctly identified by the 12 week response.
Our results do not entirely support the current European recommendation advocating 4 week response to diet alone as a predictor of treatment efficacy. Those recommendations were based largely on the findings of the 1 year INDEX trial of dexfenfluramine that weight loss ! 1.8 kg in the first 4 weeks of treatment was associated with greater likelihood of Table 2 Weight loss after 1 and 2 years of orlistat treatment in 2 y completers population, categorised by weight loss achieved during a 4 week dietary lead-in ( < 2.5 kg or ! 2.5 kg) and during first 12 weeks of diet plus drug treatment ( < 5% or ! 5% Early response predicts 2 year weight loss A Rissanen et al Figure 2 Changes in risk factors after 1 and 2 years from start of dietary lead-in period (initial values) in patients treated with orlistat 120 mg categorised by weight loss during the first 12 weeks of drug treatment ( < 5% or ! 5%). Figure 3 Changes in body weight and risk factors after 2 years in patients with at least 5% weight loss at 12 weeks, categorised by whether or not they achieved ! 10% weight loss at 6 months.
Early response predicts 2 year weight loss A Rissanen et al sustaining a ! 10% weight loss at 1 year. 21 While it has been shown that early weight loss predicts long term weight outcome in obese patients, 9 it is unclear how this early response should be defined. Our study indicates that the prognostic value of the 4 week response does not extend to the 2 year outcome in orlistat treatment: of the 102 patients who failed to lose 2.5 kg in 4 weeks, 33 (32%) who subsequently achieved ! 5% weight loss after 12 weeks of diet plus drug therapy lost 11.3 AE 1.1% at 2 years. Adherence to this 4 week criterion for continuation of treatment could inappropriately exclude a considerable number of patients (roughly one third) from clinically worthwhile treatment.
The NICE guidance specifies that patients should meet all three criteria for continued treatment with orlistat. In the present analysis, patients who met the 4 week and 12 week weight loss criteria but failed to achieve 10% weight loss at 6 months would be discontinued from drug therapy according to the NICE recommendations. While 2 year weight loss was indeed lower in the group of subjects who lost ! 5% at 12 weeks but < 10% vs ! 10% at 6 months, they nevertheless achieved 10.1% weight loss after 2 years, a value which is consistent with considerable health benefits. Moreover, the 95% confidence intervals for the mean risk factor changes at 2 years overlapped between these groups, suggesting that there were no significant differences in the overall health benefits associated with weight loss. Accordingly, the third criterion appears to have limited specificity in identifying patients who will not achieve long-term success. In aggregate, these results suggest that the 12 week response is the single most useful clinical indicator of treatment response.
Subjects with weight loss ! 5% during the first 12 weeks of orlistat treatment had significant reductions in cardio-vascular disease risk factors after 2 years of treatment, whereas neither the weight loss in the 4 week dietary lead-in or at 6 months delineated subsets of subjects with significantly greater health benefits. These risk factor changes compare favourably with those observed in the Sibutramine Trial of Obesity Reduction and Maintenance (STORM), in which a 2 year mean weight loss of 10.2 kg in subjects who responded initially to open-label drug treatment with a weight loss ! 5% over 6 months was associated with improvements in HDL and triglyceride levels but not in total-cholesterol, plasma glucose, or blood pressure. 22 Not every patient responds to a given drug and careful selection of patients most likely to respond well to adjunctive pharmacotherapy is of utmost importance in the management of obesity, as with other chronic diseases. The present analysis suggests that ! 5% weight loss after 12 weeks of treatment with orlistat is a useful predictor of weight loss, 2 year weight maintenance and risk factor reduction, even among patients who do not appear to respond immediately to short-term dietary intervention or who do not sustain a rapid rate of weight loss from 3 -6 months of diet plus drug therapy. Thus, the currently recommended prescribing criteria appear to have considerable predictive value with the 5% weight loss in 3 months as the earliest and most specific indicator of the long-term treatment outcome.
